In vivo Longitudinal Imaging of RNAi Induced Endocrine Therapy Resistance in Breast Cancer

Endocrine therapy resistance in breast cancer is a major obstacle in the treatment of patients with estrogen receptor-positive (ER+) tumors. Herein, we demonstrate the feasibility of longitudinal, non-invasive, and semi-quantitative in vivo molecular imaging of resistance to three endocrine therapie...

Full description

Saved in:
Bibliographic Details
Published inJournal of biophotonics Vol. 13; no. 1; p. e201900180
Main Authors Biswal, Nrusingh C., Fu, Xiaoyong, Jagtap, Jaidip M., Shea, Martin J., Kumar, Vijetha, Lords, Tamika, Roy, Ronita, Schiff, Rachel, Joshi, Amit
Format Journal Article
LanguageEnglish
Published 09.10.2019
Online AccessGet full text

Cover

Loading…
More Information
Summary:Endocrine therapy resistance in breast cancer is a major obstacle in the treatment of patients with estrogen receptor-positive (ER+) tumors. Herein, we demonstrate the feasibility of longitudinal, non-invasive, and semi-quantitative in vivo molecular imaging of resistance to three endocrine therapies by using an inducible fluorescence labelled shRNA system in orthotopic mice xenograft tumors. We employed a dual fluorescent doxycycline (Dox)-regulated lentiviral inducer system to transfect ER+ MCF-7L breast cancer cells, with GFP expression as a marker of transfection, and RFP expression as a surrogate marker of Dox-induced the tumor suppressor PTEN knockdown. Xenografted MCF-7L tumor-bearing nude mice were randomized to therapies comprising estrogen deprivation, tamoxifen, or an ER degrader (fulvestrant), and an estrogen-treated control group. Longitudinal imaging was performed by a home-built multispectral imaging system based on a cooled image intensified CCD camera. The GFP signal, which corresponds to number of viable tumor cells, exhibited excellent correlation to calliper-measured tumor size (p << 0.05). RFP expression was substantially higher in mice exhibiting therapy resistance, and strongly and significantly (p < 1e-7) correlated with the tumor size progression for the mice with shRNA-induced PTEN knockdown. PTEN loss was strongly correlated with resistance to estrogen deprivation, tamoxifen, and fulvestrant therapies. In vivo images of GFP and RFP channels for treatment with (a) −Dox and (b) +Dox in mice. (c) The tumor exhibiting resistance to endocrine therapy has been demonstrated with typical images from ED+Dox and Ful+Dox.
ISSN:1864-063X
1864-0648
DOI:10.1002/jbio.201900180